UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, umeclidinium bromide 62.5 microgram/actuation + vilanterol trifenatate 25

microgram/actuation inhalation: powder for, 30 actuations, Anoro^TM Ellipta^® (Major submission). Pharmaceutical Benefits Advisory Committee.

http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/03 -2014. Published 2014. Accessed June 17, 2014.

39. Scottish Medicines Consortium. Umeclidinium bromide / vilanterol (Anoro) for Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructivew pulmonary disease (COPD). Scottish Medicines Consortium.

http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions /umeclidinium_bromide_vilanterol_Anoro. Published 2014. Accessed June 17, 2014.

40. 財團法人醫藥品查驗中心醫藥科技評估組. 迪開舒膜錠(Daxas 500 micrograms film-coated tablets)醫療科技評估報告.

http://www.nhi.gov.tw/Resource/webdata/21916_1_%E8%BF%AA%E9%96

%8B%E8%88%92%E8%86%9C%E9%8C%A0(Daxas%20500%20microgra ms%20film-coated%20tablets%20)%E9%86%AB%E8%97%A5%E7%A7%9 1%E6%8A%80%E8%A9%95%E4%BC%B0%E5%A0%B1%E5%91%8A(10 1.9.28%E6%96%B0%E5%A2%9E).pdf. Published 2012. Accessed July 18, 2014.

41. 台灣胸腔暨重症加護醫學會. 慢性阻塞性肺病 2012 診治指引.

http://web.tygh.gov.tw/chest/2012E/COPD2012..pdf. Published 2012.

Accessed.

42. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease:

current burden and future projections. The European respiratory journal 2006;

27(2): 397-412.

43. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064):

1498-1504.

44. Murray CJL, López AD, Health HSoP, Organization WH, Bank W. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 ; summary: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.

45. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine 2006; 3(11): e442.

46. 行政院衛生福利部統計處. 101 年度全民健康保險醫療統計年報二、門、

住診合計就診率統計，按性別及年齡別分 行政院衛生福利部統計處.

http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=

4718. Accessed June 18, 2014.

47. Chiang CH. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan. Respirology (Carlton, Vic) 2008; 13(5):

689-694.

48. 藥品給付規定：第六節 呼吸道藥物. 行政院衛生福利部中央健康保險署.

http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&WD _ID=849&webdata_id=2919. Accessed June 17, 2014.

49. The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD. Available from:

http://clinicaltrials.gov/ct2/show/NCT01777334?term=umeclidinium+AND+v ilanterol&rank=8 (Accessed June 18, 2014).

50. The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium. Available from:

http://clinicaltrials.gov/ct2/show/NCT01899742?term=umeclidinium+AND+v ilanterol&rank=13 (Accessed June 18, 2014).

51. 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease. Available from:

http://clinicaltrials.gov/ct2/show/NCT01316900?term=umeclidinium+AND+v ilanterol&rank=19 (Accessed June 18, 2014).

52. 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease. Available from:

http://clinicaltrials.gov/ct2/show/NCT01316913?term=umeclidinium+AND+v ilanterol&rank=20 (Accessed June 18, 2014).

53. A Study to Evaluate the Efficacy and Safety of Umeclidinium

Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Available from:

http://clinicaltrials.gov/ct2/show/NCT01822899?term=umeclidinium+AND+v ilanterol&rank=6 (Accessed June 18, 2014).

54. 財團法人醫藥品查驗中心醫藥科技評估組. 昂帝博吸入膠囊 110/50 微克 (Ultibro Breezhaler 110/50 microgram, inhalation powder hard capsules)醫療 科技評估報告. Published 2014. Accessed July 11, 2014.

附錄

第 6 節 呼吸道藥物 Respiratory tract drugs 6.1.吸入劑 Inhalants

1.乙二型擬交感神經劑（β2-agonists）、抗膽鹼劑（anticholinergics）、類固醇藥物 吸入劑（steroid inhalants）等，依「成人呼吸道疾患吸入製劑給付規定表」(91/8/1) 及「兒童呼吸道疾患吸入製劑給付規定表」規定辦理；呼吸道藥物複方製劑比 照辦理。

2.Formoterol fumarate dehydrate (如 Oxis Turbuhaler)，依「成人呼吸道疾患吸入製 劑給付規定表」(91/8/1)及「兒童呼吸道疾患吸入製劑給付規定表」規定辦理。

固定劑量吸入劑(MDI)(91/8/1) 粉狀吸入劑(DPI) 液態吸入劑 (nebulizer)

附錄表二 經濟評估文獻搜尋記錄

資料庫 查詢日期 關鍵字 篇數

PubMed

1950-2014 20140618

#2((((economic)) OR (cost))) OR (((cost-benefit analysis)) OR ((treatment outcome) AND ec))

#3 #1 AND #2

0

EMBASE

1980-2014 20140618

#2((((economic)) OR (cost))) OR (((cost-benefit analysis)) OR ((treatment outcome) AND ec))

#3 #1 AND #2

filter publication type as ‘article’ or ‘article in press’

2

Cochrane